Associations between Demodex species infestation and various types of cancer

2013 ◽  
Vol 58 (4) ◽  
Author(s):  
Özlem Sönmez ◽  
Zeliha Yalçın ◽  
Engin Karakeçe ◽  
İhsan Çiftci ◽  
Teoman Erdem
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Hair Follicles ◽  
Cancer Type ◽  
Urogenital System ◽  
Patients With Cancer ◽  
Demodex Folliculorum ◽  
Cancer Group ◽  
Breast Cancer Group ◽  
Group 5

AbstractTumor-associated immune system cells secrete protease and cytokines that can inhibit the immune response. In particular, T-cell effector functions could be inhibited, potentially causing an increase in parasitic infestations. Demodex species are common inhabitants of normal hair follicles. Humans are the specific host for two species Demodex folliculorum and D. brevis. The aim of this study was to investigate the incidence and infestation of D. folliculorum and D. brevis in patients with cancer. In the present study, 101 patients with cancer were selected from among patients who were diagnosed and treated for cancer. The cancer patients were divided into four groups according to cancer type. Slides were examined for parasites using light microscopy at magnifications of ×40 and ×100. Infestation was defined as having at least five living parasites/cm2 of skin. The ages of the patients with cancer ranged between 38 and 82 years, with a mean of 65.5±10.1 years. It was determined that 77 of the 101 (76.2%) cancer patients were positive for Demodex species. Infestation was positive in 18 (47.4%) of the 38 cases in the breast cancer group, 7 (29.2%) of the 24 cases in the lung cancer group, 5 (18.5%) of the 27 cases in the gastrointestinal system cancer group, and 2 (16.7%) of the 12 cases in the urogenital system cancer group. Results showed that the rate of Demodex species infestation was higher in patients with breast cancer. Thus, cancer — and particularly breast cancer — is a risk factor for Demodex species infestation.

CA 549 and SP2 in postoperative breast cancer patients. Comparison with CA 15.3, CEA and TPA

1995 ◽  
Vol 10 (2) ◽  
pp. 94-99 ◽  
Author(s):  
M. Torres ◽  
C. Pacheco ◽  
A. Valverde ◽  
A.C. Rebollo ◽  
A. Moral ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Statistical Analysis ◽  
Cancer Patients ◽  
Blood Donors ◽  
Serum Levels ◽  
Breast Cancer Patients ◽  
Benign Diseases ◽  
Ca 15.3 ◽  
Cancer Group ◽  
Breast Cancer Group

The levels of CA 549 and SP2 were measured in 430 subjects: 100 healthy blood donors, 130 patients with benign diseases and 200 postoperative breast cancer patients. In the latter group, the serum levels of CA 15.3, CEA and TPA were also measured. The Kolmogorov-Smirnov, Mann Whitney and McNemar tests were used for statistical analysis. The upper normal limits were established on the basis of the values obtained in the healthy blood donors group, the benign diseases group and R.O.C. analysis of the breast cancer group. They were: CA 549 = 13 U/ml, SP2 = 14 U/ml, CA 15.3 = 35 U/ml, CEA = 5 ng/ml and TPA = 110 U/ml. The sensitivity, specificity and accuracy in the breast cancer group were, respectively: CA 549 = 78.1%, 97.1% and 88%; SP2 = 21.9%, 90.4% and 57.5%; CEA = 66.7%, 95.2% and 81.5%; CA 15.3 = 80.2%, 98.1% and 89.5%, and TPA = 73.9%, 78.8% and 76.5%. Statistical analysis showed significant differences only between CA 15.3, the marker which gave the best results, and SP2 (p<0.001). There were no significant differences with the association of two or three tumor markers.

Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 515-515
Author(s):  
Frederic Amant ◽  
Valentina Nekljudova ◽  
Charlotte Maggen ◽  
Fenja Seither ◽  
Patrick Neven ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Hormone Receptor ◽  
Proportional Hazards ◽  
Cox Proportional Hazards ◽  
Breast Cancer Patients ◽  
Cancer Data ◽  
Cancer Group ◽  
Breast Cancer Group ◽  
Grade 3

515 Background: Overall a diagnosis of breast cancer during pregnancy (BCP) appears not to impact maternal prognosis if standard treatment is offered. However, caution is warranted as gestational changes in pharmacokinetics with respect to the distribution, metabolism and excretion of drugs may lead to reduced chemotherapy concentration in pregnant patients. This cohort study was designed to focus on the maternal prognosis of BCP patients that receive chemotherapy during pregnancy. Methods: The outcome of BCP patients treated with chemotherapy during pregnancy was compared to non-pregnant breast cancer patients treated with chemotherapy, diagnosed after 2000, excluding postpartum diagnosis and with an age limit of 45 years. The data was registered by two multicentric registries (the International Network of Cancer, Infertility and Pregnancy and the German Breast Cancer Group) that collect both retro-and prospectively breast cancer data. Cox proportional hazards regression was used to compare disease-free (DFS) and overall survival (OS) between both groups, adjusting for age, stage, grade, hormone receptor status, human epidermal growth factor 2 status and histology, weighted by propensity scoring in order to account for the differences in baseline characteristics between pregnant patients and controls. Results: In total, 662 pregnant and 2081 non-pregnant patients, were eligible for analysis. Median age at diagnosis was 34 (range 22-47) years for pregnant and 38 (range 19-45) years for non-pregnant patients. Pregnant patients were more likely to have stage II breast cancer (60.1% vs 56.1%, p = 0.035), grade 3 tumors (74.0% vs 62.2%, p < 0.001), hormone receptor-negative tumors (48.4% vs 34.0%, p < 0.001) or triple-negative breast cancer (38.9% vs 26.9%, p < 0.001). Median follow-up was 66 months. DFS and OS were comparable for pregnant and non-pregnant patients (DFS: HR 1.02, 95%CI 0.82-1.27, p = 0.83; OS: HR 1.08, 95% CI 0.81-1.45, p = 0.59). A subgroup analysis of 339 women that received more than 60% of chemotherapy during pregnancy (cut-off at median) revealed a comparable survival compared to non-pregnant women (DFS: HR 0.81, 95%CI 0.62-1.06, p = 0.13; OS: HR 0.85 95% CI 0.58-1.23, p = 0.39). Conclusions: Pregnancy-induced alternations in chemotherapy concentration do not seem to affect maternal prognosis in breast cancer patients. These results support initiation of chemotherapy for BCP where indicated for oncological reasons.

Risk of coronary artery disease after adjuvant radiotherapy in 29,662 early breast cancer patients: A population-based Danish Breast Cancer Group study

2021 ◽  
Vol 157 ◽  
pp. 106-113 ◽  
Author(s):  
Marie Louise Holm Milo ◽  
Lise Bech Jellesmark Thorsen ◽  
Søren Paaske Johnsen ◽  
Kirsten Melgaard Nielsen ◽  
Jan Brink Valentin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Cancer Patients ◽  
Adjuvant Radiotherapy ◽  
Population Based ◽  
Breast Cancer Patients ◽  
Cancer Group ◽  
Breast Cancer Group ◽  
Artery Disease

scholarly journals Early detection of Breast Cancer by Tumor Marker CA15.3, CA27.29 and relationship with P53 and Vitamin D

2014 ◽  
Vol 8 (1) ◽  
pp. 59-65
Author(s):  
Ryaidh Sh. Al-Hussain ◽  
Eman M. Kathaem ◽  
Luay N. Baker ◽  
Saeed H. Assi ◽  
Saad S. Abdulbaqi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Tumor Marker ◽  
Cancer Patients ◽  
The Body ◽  
Breast Cancer Patients ◽  
Cancer Group ◽  
Significant Difference ◽  
Breast Cancer Group ◽  
And Control

Breast cancer is the second most frequent cancer of women. Tumor markers are substances that can be found in the body when cancer is present. The classic tumor marker is a protein that can be found in the blood in increased levels when the cancer is present.The present study have been investigated the levels of cancer antigen CA15.3, CA27.29, P53 and Vitamin D in women with breast cancer, aged were 30-75 years old, they divided into four groups, each group composed of 50 women included breast cancer patients aged 30-59 year, breast cancer patients aged 60-75 years, milking nodules groups 30-60 year and control groups. This study showed significant P<0.05 increasing in the level of CA15.3, CA27.29 and P53 concentration in milking nodules and both breast cancer groups, also showed significant P<0.05 decreasing in vitamin D concentration in milking group and breast cancer group and significant difference in serum Ca concentration.

Patient navigation core metrics before and after implementation of a nurse navigation program at CHI St. Francis Cancer Treatment Center: A community based cancer program.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e18040-e18040
Author(s):  
Mehmet Sitki Copur ◽  
Monica McDonald ◽  
Yuzhen Zhou ◽  
Vicki Hurley ◽  
Adriene Tasa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Patient Navigation ◽  
Newly Diagnosed ◽  
Community Based ◽  
Interval Time ◽  
Cancer Group ◽  
Community Oncology ◽  
Navigation Program ◽  
Breast Cancer Group

e18040 Background: Patient navigation is an intervention to improve cancer outcomes by facilitating timely access to cancer care. Few comparative data exist about the effects of nurse navigation in core navigation metrics (CNM) in a community oncology setting. Methods: During one-year period of a community-based/patient entry-point navigation program, CNMs of newly diagnosed breast and non-breast cancer patients were collected and compared to that of a demographic and tumor characteristics-matched control group prior to navigation. Electronic medical records and tumor registry data were utilized to gather 10 CNMs and 12-mo survival. Results: 72 breast/107 non-breast newly diagnosed navigated cancer patients were compared to same number of matched patients who did not receive navigation. With navigation, significant improvements were observed in interval time to biopsy, pathologic diagnosis, oncology visit, first treatment, and frequency of ancillary consults in breast cancer group. In non-breast cancer group, significant improvements were observed in all CNMs except interval time to pathology diagnosis. Adherence to guidelines and treatment, and 12-mo survival were not different between two groups. Conclusions: A dedicated community based nurse navigation program can significantly improve CNMs and enhance care in both breast and non-breast cancer population in a community oncology setting. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document